End-of-day quote
Other stock markets
|
||
- USD | - |
05-09 | HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance | MT |
05-08 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Sales 2024 * | 60.29B 82.47B | Sales 2025 * | 62.64B 85.68B | Capitalization | 160B 219B |
---|---|---|---|---|---|
Net income 2024 * | 7.18B 9.83B | Net income 2025 * | 11.14B 15.24B | EV / Sales 2024 * | 3.62 x |
Net Debt 2024 * | 58.11B 79.49B | Net Debt 2025 * | 49.97B 68.35B | EV / Sales 2025 * | 3.35 x |
P/E ratio 2024 * |
20.2
x | P/E ratio 2025 * |
13.9
x | Employees | - |
Yield 2024 * |
5.89% | Yield 2025 * |
5.99% | Free-Float | 59.09% |
Latest transcript on Pfizer Inc
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 92-12-31 |
David Denton
DFI | Director of Finance/CFO | 59 | 22-05-01 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 20-03-31 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 17-02-22 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 13-09-26 |
1st Jan change | Capi. | |
---|---|---|
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |